LT3207035T - Junginiai ir kompozicijos, skirti moduliuoti egfr mutantinės kinazės aktyvumus - Google Patents

Junginiai ir kompozicijos, skirti moduliuoti egfr mutantinės kinazės aktyvumus

Info

Publication number
LT3207035T
LT3207035T LTEP15850314.4T LT15850314T LT3207035T LT 3207035 T LT3207035 T LT 3207035T LT 15850314 T LT15850314 T LT 15850314T LT 3207035 T LT3207035 T LT 3207035T
Authority
LT
Lithuania
Prior art keywords
compositions
compounds
kinase activities
egfr mutant
mutant kinase
Prior art date
Application number
LTEP15850314.4T
Other languages
English (en)
Inventor
Byung-Chul Suh
Paresh Devidas Salgaonkar
Jaekyoo Lee
Jong Sung Koh
Ho-Juhn Song
In Yong Lee
Jaesang Lee
Dong Sik Jung
Jung-Ho Kim
Se-Won Kim
Original Assignee
YUHAN Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55654993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3207035(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by YUHAN Corporation filed Critical YUHAN Corporation
Publication of LT3207035T publication Critical patent/LT3207035T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quick-Acting Or Multi-Walled Pipe Joints (AREA)
LTEP15850314.4T 2014-10-13 2015-10-13 Junginiai ir kompozicijos, skirti moduliuoti egfr mutantinės kinazės aktyvumus LT3207035T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462063394P 2014-10-13 2014-10-13
PCT/KR2015/010784 WO2016060443A2 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities

Publications (1)

Publication Number Publication Date
LT3207035T true LT3207035T (lt) 2020-02-25

Family

ID=55654993

Family Applications (5)

Application Number Title Priority Date Filing Date
LTEP15850314.4T LT3207035T (lt) 2014-10-13 2015-10-13 Junginiai ir kompozicijos, skirti moduliuoti egfr mutantinės kinazės aktyvumus
LTEP24166947.2T LT4421069T (lt) 2014-10-13 2015-10-13 Junginiai ir kompozicijos, skirti egfr mutantinės kinazės aktyvumų moduliavimui
LTEP21171619.6T LT3929190T (lt) 2014-10-13 2015-10-13 Junginiai ir kompozicijos, skirti moduliuoti egfr mutantinės kinazės aktyvumus
LTEP19196713.2T LT3604294T (lt) 2014-10-13 2015-10-13 Junginiai ir kompozicijos, skirti egfr mutantinės kinazės veiklos moduliavimui
LTPA2025522C LTPA2025522I1 (lt) 2014-10-13 2025-06-03

Family Applications After (4)

Application Number Title Priority Date Filing Date
LTEP24166947.2T LT4421069T (lt) 2014-10-13 2015-10-13 Junginiai ir kompozicijos, skirti egfr mutantinės kinazės aktyvumų moduliavimui
LTEP21171619.6T LT3929190T (lt) 2014-10-13 2015-10-13 Junginiai ir kompozicijos, skirti moduliuoti egfr mutantinės kinazės aktyvumus
LTEP19196713.2T LT3604294T (lt) 2014-10-13 2015-10-13 Junginiai ir kompozicijos, skirti egfr mutantinės kinazės veiklos moduliavimui
LTPA2025522C LTPA2025522I1 (lt) 2014-10-13 2025-06-03

Country Status (30)

Country Link
US (2) US9593098B2 (lt)
EP (5) EP3207035B1 (lt)
JP (3) JP6524221B2 (lt)
KR (5) KR102208775B1 (lt)
CN (2) CN106795144B (lt)
AU (1) AU2015331166B2 (lt)
BR (1) BR112017007769B1 (lt)
CA (1) CA2962914C (lt)
CY (3) CY1122737T1 (lt)
DK (4) DK4421069T3 (lt)
ES (4) ES2879474T3 (lt)
FI (3) FI3929190T3 (lt)
FR (1) FR25C1021I2 (lt)
HR (4) HRP20251702T1 (lt)
HU (4) HUE048006T2 (lt)
LT (5) LT3207035T (lt)
MX (3) MX2017003181A (lt)
NL (1) NL301329I2 (lt)
NO (1) NO2025025I1 (lt)
NZ (1) NZ730012A (lt)
PH (1) PH12017500488A1 (lt)
PL (4) PL4421069T3 (lt)
PT (4) PT3929190T (lt)
RS (4) RS67623B1 (lt)
RU (1) RU2727700C2 (lt)
SG (1) SG11201701960XA (lt)
SI (4) SI3604294T1 (lt)
SM (4) SMT202500069T1 (lt)
TW (2) TWI730331B (lt)
WO (1) WO2016060443A2 (lt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ730012A (en) * 2014-10-13 2019-06-28 Yuhan Corp Compounds and compositions for modulating egfr mutant kinase activities
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
TWI726968B (zh) 2016-01-07 2021-05-11 開曼群島商Ｃｓ醫藥技術公司 Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
AU2017269335B2 (en) * 2016-05-26 2021-07-01 Recurium Ip Holdings, Llc EGFR inhibitor compounds
KR102030886B1 (ko) * 2016-09-23 2019-10-10 재단법인 대구경북첨단의료산업진흥재단 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
CN108707139B (zh) * 2017-06-13 2021-04-06 北京鞍石生物科技有限责任公司 氨基嘧啶类化合物及其制备方法和应用
PL3658553T3 (pl) * 2017-07-28 2022-10-10 Yuhan Corporation Związki pośrednie przydatne do syntezy pochodnych aminopirymidyny, sposób ich wytwarzania oraz sposób wytwarzania pochodnych aminopirymidyny z ich zastosowaniem
IL271973B (en) * 2017-07-28 2022-08-01 Yuhan Corp An improved process for the preparation of aminopyrimidine derivatives
JP7189932B2 (ja) 2017-07-28 2022-12-14 ユハン コーポレーション タンパク質キナーゼに対する選択的阻害剤の合成に有用な中間体及びそれを調製するためのプロセス
US11267810B2 (en) * 2017-08-30 2022-03-08 Shenzhen Targetrx, Inc. Aminopyrimidine compound and composition comprising same and use thereof
CN108047207A (zh) * 2018-01-30 2018-05-18 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺氘代物及应用
CN108017633A (zh) * 2018-01-30 2018-05-11 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用
KR102871791B1 (ko) 2018-09-10 2025-10-15 미라티 테라퓨틱스, 인크. 병용 요법
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
WO2020125391A1 (zh) * 2018-12-21 2020-06-25 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的氨基嘧啶类化合物
SG11202108311RA (en) 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
AU2020240382B2 (en) * 2019-03-19 2022-08-25 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物
EA202192552A1 (ru) 2019-03-29 2021-12-17 Астразенека Аб Осимертиниб для применения в лечении немелкоклеточного рака легкого
PH12021552798A1 (en) 2019-05-14 2022-09-19 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
KR20220010731A (ko) * 2019-05-14 2022-01-26 얀센 바이오테크 인코포레이티드 이중특이성 항-EGFR/c-Met 항체와 제3 세대 EGFR 티로신 키나제 억제제에 의한 병용 요법
CN110128354A (zh) * 2019-06-20 2019-08-16 大连大学 一种5-氟-2-甲磺酰基-4-氨基嘧啶的制备方法
KR20210032093A (ko) 2019-09-16 2021-03-24 제이투에이치바이오텍 (주) Ｅｇｆｒ 돌연변이 키나제 성장 억제 효과를 나타내는 피리미딘 유도체 및 이의 의약 용도
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
EP4093394A1 (en) 2020-01-20 2022-11-30 Astrazeneca AB Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
JP7783182B2 (ja) 2020-02-12 2025-12-09 ヤンセン バイオテツク，インコーポレーテツド ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療
EP4135669A1 (en) 2020-04-14 2023-02-22 Janssen Biotech, Inc. Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
KR20210152312A (ko) * 2020-06-08 2021-12-15 주식회사 종근당 카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물
US20230321087A1 (en) 2020-09-14 2023-10-12 Janssen Pharmaceutica Nv Fgfr inhibitor combination therapies
TWI867047B (zh) * 2020-09-18 2024-12-21 南韓商沃若諾伊公司 雜芳基衍生物、其製備方法、及含彼作為活性成份之藥學組成物
TW202227425A (zh) * 2020-09-18 2022-07-16 南韓商沃若諾伊生物公司 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物
KR20220085735A (ko) * 2020-12-14 2022-06-22 보로노이바이오 주식회사 아이소옥사졸리딘 유도체 화합물 및 이의 용도
JP2024516721A (ja) * 2021-05-07 2024-04-16 ボロノイ インコーポレイテッド ヘテロアリール誘導体、これを製造する方法、およびこれを有効成分として含む薬学的組成物
AU2022271388A1 (en) 2021-05-17 2022-12-01 Voronoi Inc. Heteroaryl derivative compounds, and uses thereof
WO2022253261A1 (zh) 2021-06-01 2022-12-08 杭州领业医药科技有限公司 Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途
KR102685187B1 (ko) 2021-10-15 2024-07-16 제이투에이치바이오텍 (주) Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도
TW202342057A (zh) 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
CN119278041A (zh) 2022-03-31 2025-01-07 阿斯利康(瑞典)有限公司 用于治疗癌症的与akt抑制剂组合的表皮生长因子受体（egfr）酪氨酸激酶抑制剂
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
KR20250006237A (ko) 2022-04-28 2025-01-10 아스트라제네카 아베 축합 바이사이클릭 헤테로방향족 화합물 및 암의 치료에서의 이의 용도
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
IL317733A (en) 2022-06-27 2025-02-01 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for cancer treatment
EP4551226A1 (en) 2022-07-08 2025-05-14 Astrazeneca AB Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
WO2025017409A1 (en) 2023-07-14 2025-01-23 Janssen Biotech, Inc. Dosing regimen for therapies comprising bispecific antiegfr/c-met antibodies
EP4612147A1 (en) * 2022-11-03 2025-09-10 Voronoi Inc. Fumarate, tartrate, malate, and citrate salts of an egfr inhibitor
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
CN116655600B (zh) * 2023-05-23 2025-08-22 江南大学 一种取代的2-芳氨基嘧啶类化合物、药物组合物及其用途
AU2024337472A1 (en) 2023-09-05 2026-04-16 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer
WO2026009146A1 (en) 2024-07-01 2026-01-08 Hetero Labs Limited Benzimidazole compounds as egfr inhibitors
CA3278557A1 (en) 2024-08-13 2026-03-01 Janssen Biotech, Inc. Methods for reducing dermatologic adverse events in patients treated with egfr/met bispecific antibodies
WO2026038160A1 (en) 2024-08-13 2026-02-19 Janssen Biotech, Inc. Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
WO2026042017A1 (en) 2024-08-19 2026-02-26 Janssen Biotech, Inc. Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc)
WO2026047630A1 (en) 2024-08-31 2026-03-05 Hetero Labs Limited Heterocyclic compounds as egfr inhibitors
WO2026053183A1 (en) 2024-09-09 2026-03-12 Hetero Labs Limited Benzothiazole and benzoxazole compounds as egfr inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU725548B2 (en) 1997-03-11 2000-10-12 E.I. Du Pont De Nemours And Company Heteroaryl azole herbicides
HUP0301117A3 (en) * 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
EP1345925B1 (en) 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
MXPA04004178A (es) 2001-11-01 2004-09-06 Janssen Pharmaceutica Nv Heteroarilaminas como inhibidores de glucogeno cintasa cinasa 3beta.
KR20050084027A (ko) 2002-11-28 2005-08-26 쉐링 악티엔게젤샤프트 Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
JP4428565B2 (ja) 2004-10-05 2010-03-10 東京エレクトロン株式会社 処理液塗布装置
EP1799652A1 (en) 2004-10-13 2007-06-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
CA2590110C (en) 2004-12-30 2014-06-03 Exelixis, Inc. Kinase modulators and method of use
US20070072894A1 (en) 2005-03-24 2007-03-29 Kempf J V Synthesis of pyrroloquinoline quinone (PQQ)
JP5007029B2 (ja) 2005-07-13 2012-08-22 Ｎｔｎ株式会社 グリース組成物および該グリース封入転がり軸受
BRPI0615270A2 (pt) 2005-08-25 2009-08-04 Hoffmann La Roche pirazol fundido como inibidores de p38 map cinase
JP2007117465A (ja) 2005-10-28 2007-05-17 Sharp Corp 集塵器およびそれを備えた電気掃除機
JP2009531943A (ja) 2006-03-29 2009-09-03 ケーティーフリーテル・カンパニー・リミテッド デジタル処理装置及びこれを用いた付加サービス提供方法
WO2007117465A2 (en) 2006-03-31 2007-10-18 Abbott Laboratories Indazole compounds
MX2008013203A (es) 2006-04-12 2008-10-22 Wyeth Corp Analogos de anilino-pirimidina fenilo y benzotiofeno.
WO2008079291A2 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
NZ603525A (en) * 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
JP5918693B2 (ja) * 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
US8629132B2 (en) 2009-11-13 2014-01-14 Genosco Kinase inhibitors
CN103402997B (zh) 2011-02-25 2015-08-26 柳韩洋行 二氨基嘧啶衍生物及其制备方法
MY161925A (en) * 2011-07-27 2017-05-15 Astrazeneca Ab 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
CA2863517C (en) 2012-01-20 2019-11-05 Genosco Substituted pyrimidine compounds and their use as syk inhibitors
CN104583195B (zh) * 2012-09-12 2018-08-17 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2015025197A1 (en) * 2013-08-22 2015-02-26 Jubilant Biosys Limited Substituted pyrimidine compounds, compositions and medicinal applications thereof
WO2015094803A1 (en) 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
CN106660993B (zh) 2014-06-12 2020-09-11 上海复尚慧创医药研究有限公司 一类激酶抑制剂
MY186839A (en) 2014-06-19 2021-08-25 Takeda Pharmaceuticals Co Heteroaryl compounds for kinase inhibition
NZ730012A (en) * 2014-10-13 2019-06-28 Yuhan Corp Compounds and compositions for modulating egfr mutant kinase activities
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用

Also Published As

Publication number Publication date
ES3009926T3 (en) 2025-03-31
JP6754864B2 (ja) 2020-09-16
CY2025016I1 (el) 2026-02-25
TWI730331B (zh) 2021-06-11
RU2017116598A (ru) 2018-11-21
SMT202100266T1 (it) 2021-07-12
CN111686110A (zh) 2020-09-22
HUE048006T2 (hu) 2020-05-28
NZ730012A (en) 2019-06-28
BR112017007769A2 (pt) 2018-01-16
WO2016060443A2 (en) 2016-04-21
SG11201701960XA (en) 2017-04-27
SI3929190T1 (sl) 2025-04-30
DK3929190T3 (da) 2025-02-24
FI4421069T3 (fi) 2026-01-21
MX385942B (es) 2025-03-18
RS66529B1 (sr) 2025-03-31
EP3207035B1 (en) 2019-11-20
EP3604294A1 (en) 2020-02-05
HUE070874T2 (hu) 2025-07-28
JP2020196740A (ja) 2020-12-10
EP3929190A1 (en) 2021-12-29
RU2727700C2 (ru) 2020-07-23
PL3604294T3 (pl) 2021-11-02
CN106795144B (zh) 2020-06-16
DK4421069T3 (da) 2026-01-19
DK3207035T3 (da) 2020-01-27
SMT202500500T1 (it) 2026-03-09
KR20170066650A (ko) 2017-06-14
NO2025025I1 (no) 2025-06-05
KR102073854B1 (ko) 2020-02-05
PH12017500488A1 (en) 2017-07-31
HRP20250213T1 (hr) 2025-04-25
RS61865B1 (sr) 2021-06-30
CA2962914A1 (en) 2016-04-21
ES2879474T3 (es) 2021-11-22
LT4421069T (lt) 2026-02-10
HUS2500023I1 (hu) 2025-06-28
PT3207035T (pt) 2020-02-19
PL4421069T3 (pl) 2026-03-23
PT3604294T (pt) 2021-07-29
PL3207035T3 (pl) 2020-06-01
US20160102076A1 (en) 2016-04-14
US9593098B2 (en) 2017-03-14
SI4421069T1 (sl) 2026-03-31
RU2020123547A (ru) 2020-08-18
CA2962914C (en) 2018-10-23
RS67623B1 (sr) 2026-02-27
PT4421069T (pt) 2026-01-12
LT3604294T (lt) 2021-07-26
MX2021010761A (es) 2022-06-09
AU2015331166A1 (en) 2017-03-30
RS59900B1 (sr) 2020-03-31
EP4421069A1 (en) 2024-08-28
BR112017007769B1 (pt) 2023-10-10
EP3604294B1 (en) 2021-05-05
SMT202500069T1 (it) 2025-03-12
JP6524221B2 (ja) 2019-06-05
HRP20251702T1 (hr) 2026-03-13
FIC20250023I1 (fi) 2025-06-06
AU2015331166B2 (en) 2018-04-26
FI3929190T3 (fi) 2025-02-28
JP2017530999A (ja) 2017-10-19
KR20240074820A (ko) 2024-05-28
KR20230010836A (ko) 2023-01-19
FR25C1021I1 (fr) 2025-08-01
LT3929190T (lt) 2025-02-25
SMT202000059T1 (it) 2020-03-13
KR20200014944A (ko) 2020-02-11
ES3058882T3 (en) 2026-03-13
HRP20210949T1 (hr) 2021-09-03
RU2017116598A3 (lt) 2018-11-21
CY1122737T1 (el) 2021-03-12
JP2019163277A (ja) 2019-09-26
TW201938553A (zh) 2019-10-01
TW201619150A (zh) 2016-06-01
CN106795144A (zh) 2017-05-31
SI3604294T1 (sl) 2021-08-31
KR102662358B1 (ko) 2024-04-30
FR25C1021I2 (fr) 2026-02-06
EP3929190B1 (en) 2024-12-25
EP3207035A4 (en) 2018-03-14
TWI664173B (zh) 2019-07-01
KR102487451B1 (ko) 2023-01-11
HUE054848T2 (hu) 2021-09-28
WO2016060443A3 (en) 2016-06-23
MX2020002168A (es) 2021-09-07
NL301329I2 (nl) 2025-09-09
LTPA2025522I1 (lt) 2025-06-25
KR20210011068A (ko) 2021-01-29
ES2770058T3 (es) 2020-06-30
CN111686110B (zh) 2023-06-16
HRP20200201T1 (hr) 2020-05-15
PL3929190T3 (pl) 2025-06-09
EP4725554A2 (en) 2026-04-15
PT3929190T (pt) 2025-02-19
USRE50528E1 (en) 2025-08-12
SI3207035T1 (sl) 2020-04-30
CY2025016I2 (el) 2026-02-25
CY1124359T1 (el) 2022-07-22
EP4421069B1 (en) 2025-12-10
KR102208775B1 (ko) 2021-01-28
DK3604294T3 (da) 2021-06-28
MX2017003181A (es) 2017-07-20
EP3207035A2 (en) 2017-08-23

Similar Documents

Publication Publication Date Title
HUS2500023I1 (hu) Vegyületek és készítmények EGFR mutáns kináz aktivitás modulására
IL286669A (en) Compounds and methods for modulating tmprss6 expression
IL273058A (en) Compositions and methods for modulation of PKK expression
ZA201801600B (en) Compounds and methods for modulating angiotensinogen expression
SG11201802798WA (en) Compounds, compositions, and methods for modulating cftr
IL246879B (en) Preparations of Epilimod and methods of using them
PT3114282T (pt) Relvado misto
PL3113774T3 (pl) Kompozycje grapiprantu i sposoby ich zastosowania
GB201409661D0 (en) Novel compounds and their use as kinase inhibitors
GB201405532D0 (en) Novel compounds and their use as Kinase inhibitors